Global Waldenstrom Macroglobulinemia (WM) Market Spotlight Report 2021: Treatments, Epidemiology, Disease Background, Pipeline, Recent Events, Opportunity, Clinical Trials, Marketed Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Waldenstrom Macroglobulinemia (WM)” report has been added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the Waldenstrom Macroglobulinemia (WM) market, comprising key marketed and pipeline drugs, probability of success, clinical trials, upcoming events, recent events and analyst opinion, a 10-year disease incidence forecast, and presenting drug-specific revenue forecasts.

Key Takeaways

The publisher estimates that in 2017, there were approximately 5,330 incident cases of Waldenstrom macroglobulinemia (WM) in people aged 40 years and over worldwide, and forecasts that number to increase to 6,920 incident cases by 2026.

It is estimated that the majority of diagnosed cases worldwide were in males in 2017.

Worldwide, incident cases of WM are highest among individuals aged 60-79 years. Imbruvica and tirabrutinib, two small molecule tyrosine kinase inhibitors, are the only marketed drugs for WM. These therapies are administered via the oral route.

The majority of industry-sponsored drugs in active clinical development for WM are in Phase II, with only two drugs in Phase III. Therapies in development for WM focus on targets such as B-cell lymphoma 2 (Bcl-2)/Bcl-2 family, Bruton’s tyrosine kinase, chemokine receptor 4, lipid rafts, casein kinase 1 epsilon, PI3K/AKT pathway, p110 delta/PIK3CD, and proteasome. These drugs are administered via the oral, intravenous, and subcutaneous routes.

An expected CHMP opinion for Brukinsa is the only high-impact upcoming event for drugs in the WM space. The overall likelihood of approval of a Phase I hematologic cancer asset is 9.2%, and the average probability a drug advances from Phase III is 60%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that almost all trials for WM have been in the early and mid-phases of development, with 94% of trials in Phase I-II, and only 6% in Phase III-IV.

The US has a substantial lead in the number of WM clinical trials globally. The UK and France lead the major European markets, while China has the top spot in Asia.

Clinical trial activity in the WM space is dominated by completed trials. Takeda has the highest number of completed clinical trials for WM, with 11 trials.

Bristol Myers Squibb, Johnson & Johnson, and Takeda lead the industry sponsors with the highest overall number of clinical trials for WM.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

• Chemotherapy
• Targeted drugs
• Biological therapy or immunotherapy
• Plasmapheresis
• Stem cell transplantation (SCT)

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

• LOXO-305 for WM (December 5, 2020)
• Aliqopa for WM (October 14, 2020)
• Brukinsa for WM (December 16, 2019)
• Mavorixafor for WM (July 17, 2019)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

• Sponsors by status
• Sponsors by phase

BIBLIOGRAPHY

• Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/15fkd

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900